Literature DB >> 8884035

Psychotropic medication and insomnia complaints in two epidemiological studies.

M M Ohayon1, M Caulet.   

Abstract

OBJECTIVE: This study compared prescribed psychotropic medication patterns for reported sleep disorders in French and Quebec samples.
METHOD: The first study was undertaken in France (N = 5622) and the second in the metropolitan area of Montreal (N = 1722). Lay interviewers used a specialized knowledge-based system for the purpose of evaluating sleep disorders by telephone.
RESULTS: Results showed similar prevalence of insomnia complaints in both samples (20.1% and 17.8%, respectively). A higher level of psychotropic consumption was found in France (11.7% [95% confidence interval (CI), 10.9 to 12.5]) compared with Quebec, however, where consumption was less than half the French rate (5.5% [95% CI, 4.4 to 6.6]). Both studies identified females and the elderly as the primary consumers of these drugs. For approximately two-thirds of both samples, sleep-promoting medications were prescribed for a year or longer, revealing a chronicity of the consumption. Approximately 4 out of 5 prescriptions for sleeping medications were ordered by general practitioners in both samples.
CONCLUSION: These findings clearly show a higher prevalence of psychotropic drug use in the French compared with the Quebec population. The patterns of consumption and prescription, however, are quite similar in both studies.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8884035     DOI: 10.1177/070674379604100711

Source DB:  PubMed          Journal:  Can J Psychiatry        ISSN: 0706-7437            Impact factor:   4.356


  21 in total

1.  A general model of the effects of sleep medications on the risk and cost of motor vehicle accidents and its application to France.

Authors:  J Menzin; K M Lang; P Levy; E Levy
Journal:  Pharmacoeconomics       Date:  2001-01       Impact factor: 4.981

2.  Utilization of hypnotic medication in the context of cancer: predictors and frequency of use.

Authors:  Lucie Casault; Josée Savard; Hans Ivers; Marie-Hélène Savard; Sébastien Simard
Journal:  Support Care Cancer       Date:  2011-06-03       Impact factor: 3.603

3.  [Insomnia and increased use of sleep medication among seniors: problems and alternative treatment].

Authors:  Lynda Bélanger; Annie Vallières; Charles M Morin
Journal:  Can Fam Physician       Date:  2006-08       Impact factor: 3.275

4.  Sedative medication use: prevalence, risk factors, and associations with body mass index using population-level data.

Authors:  Nicholas T Vozoris; Richard S Leung
Journal:  Sleep       Date:  2011-07-01       Impact factor: 5.849

Review 5.  Minimal interventions to decrease long-term use of benzodiazepines in primary care: a systematic review and meta-analysis.

Authors:  Kayalvili Mugunthan; Treasure McGuire; Paul Glasziou
Journal:  Br J Gen Pract       Date:  2011-09       Impact factor: 5.386

6.  Patterns and correlates of benzodiazepine use in the French general population.

Authors:  Rajaa Lagnaoui; Fanny Depont; Annie Fourrier; Abdelillah Abouelfath; Bernard Bégaud; Hélène Verdoux; Nicholas Moore
Journal:  Eur J Clin Pharmacol       Date:  2004-09       Impact factor: 2.953

Review 7.  Insomnia.

Authors:  Daniel J Buysse
Journal:  JAMA       Date:  2013-02-20       Impact factor: 56.272

8.  The economic burden of insomnia: direct and indirect costs for individuals with insomnia syndrome, insomnia symptoms, and good sleepers.

Authors:  Meagan Daley; Charles M Morin; Mélanie LeBlanc; Jean-Pierre Grégoire; Josée Savard
Journal:  Sleep       Date:  2009-01       Impact factor: 5.849

9.  Prevalence, types and possible causes of insomnia in a Swiss remand prison.

Authors:  Bernice S Elger
Journal:  Eur J Epidemiol       Date:  2004       Impact factor: 8.082

10.  Discontinuation of benzodiazepines among older insomniac adults treated with cognitive-behavioural therapy combined with gradual tapering: a randomized trial.

Authors:  Lucie Baillargeon; Philippe Landreville; René Verreault; Jean-Pierre Beauchemin; Jean-Pierre Grégoire; Charles M Morin
Journal:  CMAJ       Date:  2003-11-11       Impact factor: 8.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.